Anne-Marie Girard

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1K citations

Mcl1 Inhibitor S63845, Systems Biology, Oncology +11

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

Therese‐Marie Stachyra, Premavathy Levasseur, Marie-Claude Péchereau et al. · Journal of Antimicrobial Chemotherapy · 2009 · 171 citations · Full text

Mechanism of Action of the Antibiotic NXL101, a Novel Nonfluoroquinolone Inhibitor of Bacterial Type II Topoisomerases

Michael T. Black, Therese‐Marie Stachyra, Denis Platel et al. · Antimicrobial Agents and Chemotherapy · 2008 · 141 citations · Full text

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Patrick Casara, James Davidson, Audrey Clapéron et al. · Oncotarget · 2018 · 109 citations · Full text

<i>In Vitro</i> Antibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates

Premavathy Levasseur, Anne-Marie Girard, Monique Claudon et al. · Antimicrobial Agents and Chemotherapy · 2012 · 101 citations · Full text